These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11585636)

  • 1. Increased intrathecal production of apolipoprotein D in multiple sclerosis.
    Reindl M; Knipping G; Wicher I; Dilitz E; Egg R; Deisenhammer F; Berger T
    J Neuroimmunol; 2001 Oct; 119(2):327-32. PubMed ID: 11585636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
    Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Pashenkov M; Jin JP; Link H
    J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Nennesmo I; Kouwenhoven M; Huang YM; Link H; Pashenkov M
    J Neuroimmunol; 2005 Feb; 159(1-2):165-76. PubMed ID: 15652416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy.
    Huang YC; Lyu RK; Tseng MY; Chang HS; Hsu WC; Kuo HC; Chu CC; Wu YR; Ro LS; Huang CC; Chen CM
    J Neuroimmunol; 2009 Jan; 206(1-2):100-5. PubMed ID: 19049845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system.
    Trojano M; Avolio C; Ruggieri M; De Robertis F; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Feb; 4(1):39-44. PubMed ID: 9532592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy.
    Sainaghi PP; Collimedaglia L; Alciato F; Leone MA; Naldi P; Molinari R; Monaco F; Avanzi GC
    Cytokine; 2010 Aug; 51(2):138-43. PubMed ID: 20538476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients.
    Terrisse L; Poirier J; Bertrand P; Merched A; Visvikis S; Siest G; Milne R; Rassart E
    J Neurochem; 1998 Oct; 71(4):1643-50. PubMed ID: 9751198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases.
    Nagai A; Murakawa Y; Terashima M; Shimode K; Umegae N; Takeuchi H; Kobayashi S
    Neurology; 2000 Dec; 55(12):1828-32. PubMed ID: 11134381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.
    Heming M; Schulte-Mecklenbeck A; Brix T; Wolbert J; Ruland T; Klotz L; Meuth SG; Gross CC; Wiendl H; Meyer Zu Hörste G
    Front Immunol; 2019; 10():515. PubMed ID: 30984164
    [No Abstract]   [Full Text] [Related]  

  • 11. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
    Kastenbauer S; Koedel U; Wick M; Kieseier BC; Hartung HP; Pfister HW
    J Neuroimmunol; 2003 Apr; 137(1-2):210-7. PubMed ID: 12667665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of Gas6 protein concentration in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
    Sainaghi PP; Collimedaglia L; Alciato F; Leone MA; Puta E; Naldi P; Castello L; Monaco F; Avanzi GC
    J Neurol Sci; 2008 Jun; 269(1-2):138-42. PubMed ID: 18279894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies.
    Ruiz M; Puthenparampil M; Campagnolo M; Castellani F; Salvalaggio A; Ruggero S; Toffanin E; Cacciavillani M; Gallo P; Franciotta D; Briani C
    J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):969-974. PubMed ID: 33850000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.
    Capodivento G; De Michelis C; Carpo M; Fancellu R; Schirinzi E; Severi D; Visigalli D; Franciotta D; Manganelli F; Siciliano G; Beronio A; Capello E; Lanteri P; Nobile-Orazio E; Schenone A; Benedetti L; Nobbio L
    J Neurol Neurosurg Psychiatry; 2021 Mar; 92(3):303-310. PubMed ID: 33093191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis.
    Nociti V; Frisullo G; Marti A; Luigetti M; Iorio R; Patanella AK; Bianco A; Tonali PA; Grillo RL; Sabatelli M; Batocchi AP
    J Neuroimmunol; 2010 Aug; 225(1-2):149-52. PubMed ID: 20510468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Maimone D; Annunziata P; Simone IL; Livrea P; Guazzi GC
    J Neuroimmunol; 1993 Aug; 47(1):55-61. PubMed ID: 8376548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
    Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
    Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-Barré syndrome.
    Péter M; Török W; Petrovics-Balog A; Vígh L; Vécsei L; Balogh G
    Sci Rep; 2020 Oct; 10(1):18380. PubMed ID: 33110173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-8 as a potential biomarker in Guillain-Barre Syndrome.
    Breville G; Lascano AM; Roux-Lombard P; Lalive PH
    Eur Cytokine Netw; 2019 Dec; 30(4):130-134. PubMed ID: 32096474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.
    Zhornitsky S; McKay KA; Metz LM; Teunissen CE; Rangachari M
    Mult Scler Relat Disord; 2016 Jan; 5():53-65. PubMed ID: 26856944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.